Accel Diagnostics
Medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Convertible | ||
| Total Funding | 000k | ||
Related Content
Accel Diagnostics specializes in developing and distributing rapid Point of Care (POC) blood assays and laboratory tests. The company's core products include fully integrated, disposable diagnostic tests that can be used by patients for self-testing, with results monitored remotely by physicians through a companion mobile app. This ensures continuous patient care and real-time physician oversight. Additionally, Accel Diagnostics offers a range of rapid assays designed to support laboratory and clinical research, including sensitive immunoassays capable of detecting and quantifying multiple biomarkers from minimal blood samples. The company serves healthcare providers, research institutions, and clinical laboratories, operating in the medical diagnostics and biotechnology markets. Its business model revolves around the sale of diagnostic tests and companion software, generating revenue through product sales and potentially through data analytics services.
Keywords: rapid diagnostics, Point of Care, blood assays, remote monitoring, immunoassays, clinical research, biosensors, COVID-19 antibody test, disposable tests, mobile app.